Death from pulmonary interstitial fibrosis due to pingyangmycin and cyclophosphamide in a patient with Hodgkin′s lymphoma
10.3760/cma.j.issn.1008-5734.2018.06.016
- VernacularTitle:平阳霉素和环磷酰胺致霍奇金淋巴瘤患者肺间质纤维化并死亡
- Author:
Jiqiu HOU
1
;
Hongmei ZHANG
;
Jinbao XIAO
;
Ping LI
Author Information
1. 吉林大学第二医院药学部,长春,130021
- Publication Type:Journal Article
- Keywords:
Cyclophosphamide;
Pulmonary fibrosis;
Pingyangmycin
- From:
Adverse Drug Reactions Journal
2018;20(6):456-458
- CountryChina
- Language:Chinese
-
Abstract:
A 46-year-old male patient with Hodgkin′s lymphoma received ABVD regimen with pingyangmycin,epirubicin,vindesine,and dacarbazine (the chemotherapy cycle was 28 days). After 4 cycles of chemotherapy,the patient developed obvious dyspnea,which became more serious after activity and did not improve after oxygen inhalation and glucocorticoid treatment. The chemotherapy regimen was changed to CHOPE regimen with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide (the chemotherapy cycle was 28 days). After 1 cycle of the CHOPE chemotherapy,the patient′s dyspnea aggravated. Blood oxygenation analysis showed pH 7.5,arterial oxygen partial pressure 51 mmHg,partial pressure of arterial blood carbon dioxide 32 mmHg,and blood oxygen saturation 0.89. A lot of Velcro rales could be auscultated in bilateral lungs. Chest CT examination showed bilateral pulmonary interstitial changes. Pulmonary interstitial fibrosis induced by pingyangmycin and cyclophospha-mide was considered. The patient was given treatments of IV infusions of methylprednisolone sodium succinate and ambroxol hydrochloride injection,and noninvasive mechanical ventilation. But his condition aggravated progressively and eventually died due to respiratory failure.
